INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

17.06.25 16:00 Uhr

Werte in diesem Artikel
Aktien

85,24 EUR 1,04 EUR 1,24%

NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.  Although the AERIFY-1 late-stage trial met the primary endpoint with a statistically significant and clinically meaningful impact, the AERIFY-2 trial failed to reach the same goal. 

On this news, Sanofi's American Depositary Receipt ("ADR") price fell $2.98 per ADR, or 5.69%, to close at $49.37 per ADR on May 30, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sanofi---sny-302483336.html

SOURCE Pomerantz LLP

Ausgewählte Hebelprodukte auf Sanofi

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sanofi

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Sanofi S.A.

Wer­bung

Analysen zu Sanofi S.A.

DatumRatingAnalyst
12.06.2025Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.06.2025Sanofi BuyJefferies & Company Inc.
04.06.2025Sanofi OutperformBernstein Research
03.06.2025Sanofi HoldDeutsche Bank AG
02.06.2025Sanofi OutperformBernstein Research
DatumRatingAnalyst
12.06.2025Sanofi BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
05.06.2025Sanofi BuyJefferies & Company Inc.
04.06.2025Sanofi OutperformBernstein Research
02.06.2025Sanofi OutperformBernstein Research
02.06.2025Sanofi BuyUBS AG
DatumRatingAnalyst
03.06.2025Sanofi HoldDeutsche Bank AG
02.06.2025Sanofi NeutralJP Morgan Chase & Co.
02.06.2025Sanofi HoldDeutsche Bank AG
30.05.2025Sanofi NeutralJP Morgan Chase & Co.
08.05.2025Sanofi NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
18.12.2024Sanofi SellDeutsche Bank AG
17.12.2024Sanofi SellDeutsche Bank AG
06.12.2024Sanofi SellDeutsche Bank AG
03.12.2024Sanofi SellDeutsche Bank AG
28.10.2024Sanofi SellDeutsche Bank AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sanofi S.A. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen